GO
Loading...

Merck & Co Inc

More

  • Game Plan Friday, 13 Apr 2007 | 8:10 PM ET

    It’s Friday, and that means it’s time to huddle up for Cramer’s plays for next week. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Stocks closed higher Friday following positive earnings guidance from a handful of big companies, pushing the major indexes up for the week. Bullish quarterly earnings forecasts by both Merck and McDonald's lifted the Dow Jones Industrial Average, which ended up 0.4% for the week. The S&P 500 rose 0.6%, while the Nasdaq climbed 0.8%.

  • Merck's Lucky Friday Friday, 13 Apr 2007 | 12:40 PM ET

    Superstition be darned. Shares of Dow component Merck are trading above $50 intra-day. That's the first time they've crossed 50 since October 9, 2003--nearly one year before the company pulled Vioxx off the market. So, what's going on?

  • Merck shares rose sharply Friday after the drugmaker raised its outlook for first-quarter and full-year earnings, citing strong sales across its range of products, and said a federal court judge dismissed a class-action securities lawsuit against the company.

  • CNBC's Domm: Today's Agenda in the Markets Friday, 13 Apr 2007 | 8:36 AM ET

    Inflation data could play a big role in setting the course for stocks, which so far are looking for direction ahead of the opening. Asia markets were mostly lower, while Europe's stock markets this morning are mostly higher.

  • Merck's new pain reliever drug Arcoxia, which was proposed as a successor to Vioxx, was rejected by a federal health advisory panel. A Food and Drug Administration drug safety expert earlier told the panel that the drug may increase substantially the risk of stroke and heart attack and is no more effective for pain relief than other medicines in the same class.

  • MedImmune Hires Goldman to Explore Sale Thursday, 12 Apr 2007 | 11:09 AM ET

    U.S. biotechnology company MedImmune  has hired Goldman Sachs to explore a sale of the company, which has a market capitalization of $8.8 billion, people familiar with the situation said on Thursday.

  • Daughter of Vioxx Tuesday, 10 Apr 2007 | 4:31 PM ET

    Since another pharmaceutical industry blog has already posted an item about this under the title, "Son of Vioxx...." and since I don't want to be accused of plagiarism or sexism I've opted for "Daughter of Vioxx".

  • Despite a volatile first quarter, stocks aren't much above where they were at the beginning of the year. But even if the major averages aren't showing big gains, smart investors know where to look for growth opportuntities.

  • What If Iran Goes Awry? Monday, 2 Apr 2007 | 6:42 PM ET

    Iranian mischief is the single most bankable trend in the world, Cramer says. So he’s got a doomsday portfolio for you just in case events take a turn for the worst. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Stocks closed sharply lower after being down all day on Fed Chairman Ben Bernanke's remarks that "economic uncertainty" has increased. "The market has these little flips up and down but it's been quiet and down all day long," said Mike Driscoll, head of listed trading at Bear Stearns

  • Stocks Close Lower As Housing Concerns Sideline Buyers Tuesday, 27 Mar 2007 | 6:49 PM ET

    Stocks closed lower after a new warning from the housing industry kept buyers out of the market. "Even though we may test the lows just because some short-term investors may get out of the way, this market has been really good shape," said Richard Steinberg, president and chief investment officer at Steinberg Global Asset Management. "If we pull back, investors should be reassessing their portfolios and looking to pick up bargains."

  • Jury Rules for Merck in Latest Vioxx Case Tuesday, 27 Mar 2007 | 11:51 AM ET

    Plaintiff Frank Schwaller sued Merck after his wife, Patricia, took Vioxx for 20 months for shoulder pain before dying from a heart attack in August 2003.

  • Stocks ended mixed as the major markets bounced off the day's lows following disappointing monthly housing data. "We may see some weakness, but overall we like the market. I think the direction is going to be higher," said Sebastian Leburn, chief investment officer at Weiss Capital Management, in an interview with CNBC.com.

  • Merck, Schering To Develop Combo Pill With Lipitor Monday, 26 Mar 2007 | 12:32 PM ET

    Merck and Schering-Plough said on Monday they were beginning development of a cholesterol-lowering product that would combine their Zetia drug with Pfizer's Lipitor.

  • Angered U.S. Firm Excludes Thailand from New Drugs Wednesday, 14 Mar 2007 | 8:04 PM ET

    U.S. drugs giant Abbott Laboratories said it would stop launching new medicines in Thailand in protest at the army-backed government's move to override international drug patents.

  • Merck's CEO Got $8.04 Million in 2006 Compensation Tuesday, 13 Mar 2007 | 4:40 AM ET

    The chief executive of Merck received compensation the company valued at $8.04 million last year, according to a regulatory filing Monday.

  • Painkiller Vioxx contributed to an Idaho postal worker's heart attack, a jury in Atlantic City ruled Monday, reversing the verdict in the man's first trial and hitting drugmaker Merck with a total of $47.5 million in damages.

  • Stocks closed higher as investors overcame concerns about subprime lending to spark a late-day rally.  "We're going through a short-term bounce," Mark Arbeter, Chief Technical Strategist at Standard & Poor's, told CNBC.  "Volume, so far, on the upside has been fairly light, which is not encouraging. "

  • Vioxx Verdict Upheld; Merck Boosts CEO's Salary Tuesday, 6 Mar 2007 | 2:33 AM ET

    A judge in the New Jersey Vioxx personal injury trial on Monday rejected a motion that would give one of the plaintiffs in the trial another opportunity to collect damages based on negligence from drug maker Merck.

Most Popular Video

Wednesday, 16 Apr 2014 | 4:03 PM ET

Providing instant analysis to Google's quarterly numbers, with Victor Anthony, Topeka Capital Markets; Andrew Stoltmann of Stoltmann Law Offices; CNBC contributor Michael Yoshikami; "Fast Money" trader Tim Seymour; CNBC's Michelle Caruso-Cabrera and Dominic Chu.

Wednesday, 16 Apr 2014 | 12:35 PM ET

Intel CEO Brian Krzanich discusses some signs of stability in enterprise in the mature markets, and whether the emerging markets area steadying as well.

Wednesday, 16 Apr 2014 | 11:56 AM ET

Art Cashin, UBS director of floor operations, explains what played into yesterday's market reversal and tells what sectors are back in favor today.